ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
0/0

Search for Multi-Stage Mutation Resistant HIV Drug: A DFT Study

preprint
submitted on 02.01.2020 and posted on 02.01.2020 by Arijit Bag
Recent advances of computational methodology to predict the important properties of a drug, like IC50, LogP, CC50, etc., assist in model and in-silico characterization of these compounds as a drug for variant deadly diseases. With the help of these methodologies, the drug potency of thio-propionate derivatives of iron, ruthenium and osmium carbonyl clusters which are less toxic, water soluble and easy metabolic, are tested as HIV drug along with their metabolic probability study. It is observed that IC50 of Ru5(CO)14(m -H)(m -S(CH2)2COO-)Na+ is only 220 picomole as HIV-1 capsid A inhibitor. Its inhibition activities in other enzymatic processes involved in the HIV life cycle in the human body are also studied and compared with the most used market available drugs. It is observed that this modeled compound shows excellent inhibition activities at different stages of HIV life-span inside the human body and could be considered as a multi-stage, mutation resistant HIV drug.

Funding

No funding to report.

History

Email Address of Submitting Author

bagarijit@gmail.com

Institution

Maulana Abul Kalam Azad University of Technology

Country

India

ORCID For Submitting Author

0000-0002-0177-9605

Declaration of Conflict of Interest

There is no conflict of interest.

Version Notes

Initial Draft version.

Exports

Read the published paper

in SSRN Electronic Journal

Logo branding

Exports